New drug combo with radiation for advanced MSS colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced colorectal cancer that is MSS (microsatellite stable) and has spread beyond the colon.
- You have already tried at least two standard treatments (like chemo with 5-FU, oxaliplatin, irinotecan, Avastin, or Erbitux) and they stopped working or caused bad side effects.
- You can still perform your daily activities (ECOG score 0 or 1) and are expected to live at least 3 months.
- You have tumors that can be measured with scans.
- You have not had immunotherapy targeting PD-1, PD-L1, or CTLA-4 before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of precisely targeted radiation (SBRT) with two drugs: fruquintinib (a pill that blocks blood supply to tumors) and antibodies that boost your immune system to fight cancer (PD-1 and CTLA-4 inhibitors). It is for people with advanced colorectal cancer who have already tried two standard chemotherapy treatments.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This study tests a combination of an immunotherapy drug, a targeted therapy, and a type of low-dose radiation before standard third-line treatment in patients with colorectal cancer that has spread to the liver. The goal is to see if this approach is safe and helps shrink tumors or slow cancer growth.
This trial tests a combination of two drugs (fruquintinib and adebrelimab) plus low or high dose radiation for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.